Skip to main content

Table 1 DMBA-induced tumours in PPARγ-WT and PPARγ-MG KO mice

From: Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression

  DMBA Only-treated mice DMBA + ROSI-treated mice
  PPARγ-WT (n = 25) PPARγ-MG KO (n = 39) PPARγ-WT (n = 34) PPARγ-MG KO (n = 17)
Mammary tumour type   Tumours/Mouse (# Tumours)  
Benign tumour 0.20 (5) 0.26 (10) 0.15 (5) 0.18 (3)
  Squamous cyst 0.12 (3) 0.08 (3) 0.09 (3) 0.06 (1)
  Spindle tumour 0.04 (1)
  Adenoma 0.04 (1) 0.06 (2)
  Lipoma 0.03 (1)
  Other 0.15 (6) 0.12 (2)
Squamous cell carcinoma 0.08 (2) 0.03 (1) 0.26 (9) 0.29 (5)
Spindle cell carcinoma 0.08 (2)
Adenocarcinoma 0.12 (4)
Other carcinoma 0.08 (2) 0.03 (1) 0.29 (5)
Total mammary tumours 0.44 (11) 0.31 (12) 0.53 (18) 0.76 (13)
   Benign mammary 0.20 (5) 0.26 (10) 0.15 (5) 0.18 (3)
   Malignant mammary 0.24 (6) 0.05 (2) 0.38 (13) 0.59 (10)
Non-mammary tumour/tissue affected   Tumours / Mouse (# Tumours)  
   Skin 0.20 (5) 0.41 (16) 0.35 (12) 0.41 (7)
   Ovarian/Uterine 0.24 (6) 0.26 (10) 0.26 (9) 0.13 (3)
   Thymus 0.40 (10) 0.10 (4) 0.15 (5) 0.06 (1)
   Spleen 0.04 (1) 0.03 (1)
   Liver 0.48 (12) 0.13 (5) 0.26 (9) 0.06 (1)
   Lung 0.20 (5) 0.08 (3) 0.15 (5) 0.06 (1)
   Gastrointestinal 0.04 (1) 0.05 (2) 0.06 (2) 0.06 (1)
   Lymphoma 0.13 (4) 0.03 (1)
Total tumours 2.04 (51) 1.46 (57) 1.79 (61) 1.59 (27)
   Benign total 0.64 (16) 0.82 (32) 0.74 (25) 1.06 (18)
   Malignant total 1.40 (35) 0.64 (25) 1.05 (36) 0.53 (9)
  1. The number of breast tumours per mouse (multiplicity) is indicated with the total number in parenthesis. Mammary tumours were also sub-stratified and expressed as multiplicity of benign, malignant, and metastatic tumours per genotype and treatment. Examples of benign mammary tumour subtypes are also indicated. For non-mammary tissue, the numbers of each tumour per mouse is also indicated with the total number in parenthesis. Finally, total tumours were sub-stratified and expressed as the multiplicity of benign, malignant, and metastatic tumours per genotype and treatment.